Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: 177Lu-dotatate(Lu-PRRT) is a valid therapeutic option in advanced G1-G2 pancreatic neuroendocrine tumors (P-NETs)
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Sansovini M
Authors: Sansovini M, Severi S, Nicolini S, Ianniello A, Ambrosetti A,
#1132 177Lu-Dotatate Re-Treatment in G1-G2 Gastro-Entero-Pancreatic (GEP) NETs
Introduction: PRRT is a valid and well tollerated therapy for G1-G2GEP-NETs. A median PFS of >22 mo. has been reported after PRRT and OS of > 5 years is frequent.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Severi S
Authors: Stefano S, Maddalena S, Ianniello A, Nicolini S, Caroli P,
Keywords: PRRT, GEP-NET, re-treatment,
Introduction: The best-known altered metabolism in cancer is an increased glycolysis. FDG-PET allow us to obtain in vivo imaging of this metabolic abnormality which is an hallmark of tumor aggressiveness.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Sansovini M
Authors: Sansovini M, Stefano S, Ianniello A, Nicolini S, Fantini L,
Keywords: PRRT, neuroendocrine, FDG-PET,
Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 <20%) and neuroendocrine carcinoma (NECs) (Ki67 >20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: IBRAHIM T
Authors: Bongiovanni A, Riva N, Monti M, Ianniello A, Pieri F,
Keywords: GEP-NEC,chemotherapy,